March 24, 2017
Metastasis is common in MCC ― the cancer spreads in about a third of patients. The federal agency has granted avelumab (pronounced a-VELL-oo-mab) a broad approval, for use in any adult or adolescent patient with metastatic MCC.The approval as a first- and second-line therapy “is a really big deal,” said MCC expert Dr. Paul Nghiem of the University of Washington and Fred Hutchinson Cancer Research Center, who was a senior investigator on the avelumab trial. Nghiem’s team conducted foundational work on the role of immune cells in MCC that paved the way for immunotherapy trials in the disease, including a trial he leads of another immunotherapy drug as a first-line therapy in advanced MCC.
Imagine being told you had a rare and exceedingly deadly cancer ― and, if that wasn’t bad enough, that there was not a single drug approved to treat your disease.
Tom Judd doesn’t have to imagine. He’s lived through it. After being diagnosed in 2013 with the skin cancer Merkel cell carcinoma, Judd’s cancer jumped from his face throughout his body, growing until it interfered dangerously with organ function. By early 2015, the cancer that some of his doctors had never heard of had nearly killed him despite surgery, radiation and chemotherapy.
The authoritative source on Merkel cell carcinoma.
August 4, 2020
- What is a Merkel cell?
- What is Merkel cell carcinoma?
- Symptoms & appearance of Merkel cell carcinoma
- Causes of Merkel cell carcinoma
- Surgical excision
- Mohs micrographic surgery
- Radiation therapy
- Complementary & alternative therapies
- Clinical trials
- Adjuvant Avelumab in Merkel Cell Carcinoma Trial